Bio-Rad Laboratories, Inc. Introduces New Bio-Plex Pro™ Cell Signaling Assays
Published: Jul 24, 2012
The 34 magnetic bead–based immunoassays (23 phosphoprotein and 11 total protein targets) have been reformulated and optimized to provide exceptional sensitivity, high specificity, and improved performance over western blot and ELISA methods. They are available in singleplex sets and custom premixed all-in-one kit formats.
Bio-Plex Pro cell signaling assays can be used with lysates derived from adherent cells, suspension cells, or tissue samples. This appeals to researchers in areas such as cancer/oncology, inflammatory and autoimmune diseases, metabolic diseases, neurological disorders, cardiovascular disorders, and toxicology.
Dave Clarke, a postdoctoral research associate in the department of biological engineering at MIT, has successfully tested the new cell signaling assays. He is particularly satisfied with the balance between multiplexing and sample throughput, which allows him to build mathematical models of hepatocyte signal transduction in response to inflammation.
“Bio-Rad’s Bio-Plex Pro cell signaling assays are reliable and give us the quantitative data we need while being relatively easy to perform,” said Dr Clarke. “They fill a niche that no other assay currently fills.”
Bio-Plex Pro assays provide many advantages over other xMAP and ELISA offerings, including:
•Better performance — broader dynamic range, for increased confidence in sample detection, and higher sensitivity (detection of analyte in as little as 0.04 µg total lysate per assay well)
•Flexible ordering options — order singleplex sets or visit www.bio-rad.com/assaybuilder to configure a custom premixed kit
The Bio-Plex Pro cell signaling assays are compatible with all Bio-Plex® readers for life science research, as well as Luminex 100/200, FLEXMAP 3D, and MAGPIX instruments.
For more information on Bio-Rad’s Bio-Plex product portfolio, please visit www.bio-rad.com/bioplex.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
xMAP, Luminex, FLEXMAP 3D, and MAGPIX are trademarks of Luminex Corporation.
For more information contact:
Bio-Rad Laboratories, Inc.
312-997-2436 x 112